Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dexamethasone + ranibizumab + verteporfin
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravitreal, Intravenous
01
Overview
This is a combination therapy consisting of dexamethasone (a synthetic glucocorticoid corticosteroid), ranibizumab (a monoclonal antibody fragment targeting vascular endothelial growth factor A), and verteporfin (a photosensitizer used in photodynamic therapy). The combination is primarily investigated for the treatment of neovascular age-related macular degeneration (AMD) and choroidal neovascularization. Dexamethasone reduces ocular inflammation by suppressing immune responses; ranibizumab inhibits VEGF-A to prevent abnormal blood vessel growth and leakage; verteporfin, when activated by light during photodynamic therapy, produces reactive oxygen species that occlude abnormal blood vessels. Clinical studies have shown that this triple regimen can reduce the number of retreatment visits compared to anti-VEGF monotherapy while maintaining similar vision outcomes[1][2][4].
- Other names
- dexamethasone + ranibizumab + verteporfintriple therapy for neovascular AMD
02
Targets
VEGFA (Vascular endothelial growth factor A)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on dexamethasone + ranibizumab + verteporfin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dexamethasone + ranibizumab + verteporfin.